Thomas W. Johnson1, BSc, MBBS, MD, FRCP; Nikhil Joshi1, MBBS, PhD
1. Bristol Heart Institute, Bristol, United Kingdom
We live in extraordinary times. The current COVID crisis has understandably overshadowed developments in cardiovascular medicine over the last few months. However, it is important to reflect that, even at the COVID peak, daily deaths from COVID-19 and cardiovascular disease were 7,504 and 48,742, respectively.
During European lockdown, the results of the ISCHEMIA trial were published1 and an opportunity to pore over the supplementary data of this landmark trial was made available to all. Contemporary optimal medical therapy (OMT) demonstrated equivalence to an invasive strategy in a stable cohort of patients with symptoms of angina and evidence of moderate to ...